<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678312</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B2319</org_study_id>
    <secondary_id>2015-004207-22</secondary_id>
    <nct_id>NCT02678312</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure</brief_title>
  <official_title>Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared With Enalapril in Pediatric Patients From 1 Month to &lt; 18 Years of Age With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consist of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the
      way the body absorbs, distributes and removes the drug LCZ696. This will help determine the
      proper dose of LCZ696 for Part 2 of the study.

      The purpose for Part 2 is to compare the effectiveness and safety of LCZ696 with enalapril in
      pediatric heart failure patients over 52 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Anticipated">April 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Maximum drug concentration in plasma (Cmax)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 8, 10, and optional 24 hours post dosing</time_frame>
    <description>Cmax will be determined for LCZ696 analytes (sacubitril, LBQ657, and valsartan) by using non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 8, 10, and optional 24 hours post dosing</time_frame>
    <description>Tmax will be determined for LCZ696 analytes (sacubitril, LBQ657, and valsartan) by using non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): area under the plasma concentration-time curve from time zero to infinity (AUCinf) and area under the plasma concentration-time curve from time zero to last (AUClast)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 8, 10, and optional 24 hours post dosing</time_frame>
    <description>AUCinf and AUClast will be determined for LCZ696 analytes (sacubitril, LBQ657, and valsartan) by using non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Clearance from plasma (CL/F)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 8, 10, and optional 24 hours post dosing</time_frame>
    <description>CL/F will be determined for LCZ696 analytes (sacubitril, LBQ657, and valsartan) by using non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Time required to drug concentration to decrease by half (T 1/2)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 8, 10, and optional 24 hours post dosing</time_frame>
    <description>T 1/2 will be determined for LCZ696 analytes (sacubitril, LBQ657, and valsartan) by using non-compartmental methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacodynamics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Plasma N-terminal pro-brain natriuretic peptide (NTproBNP)</measure>
    <time_frame>0 (pre-dose) and optional 24 hours post dosing</time_frame>
    <description>The 24 hour post dose is optional depending on blood volume restrictions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacodynamics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Plasma cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>0 (pre-dose), 4 and, 8 hours post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacodynamics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Urine cGMP</measure>
    <time_frame>0 (pre-dose) hour and between 4 and 8 hours post dose</time_frame>
    <description>One urine sample at 0 hr (predose) and another urine sample between 4 to 8 hours post-dose will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacodynamics of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Plasma B-type natriuretic peptide (BNP)</measure>
    <time_frame>0 (pre-dose), 4 and 8 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of patients falling into each category based on global ranking</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The global ranking is based on clinical events such as death, listing for urgent heart transplant, mechanical life support requirement at end of study, worsening heart failure (HF), New York Heart Association (NYHA)/Ross, Patient Global Impression of Severity (PGIS), Pediatric Quality of Life Inventory (PedsQL) physical functioning domain. The primary endpoint will be derived based on 5 categories ranking worst to best outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to first occurrence of Category 1 or Category 2 event</measure>
    <time_frame>52 weeks</time_frame>
    <description>Category 1: Death; United Network for Organ Sharing (UNOS) status 1A listing for heart transplant or equivalent; Ventricular assist device (VAD)/Extracorporeal membrane oxygenation (ECMO)/mechanical ventilation requirement for life support at end of study. Category 2: Worsening HF (WHF); defined by signs and symptoms of WHF that requires an intensification of HF therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from baseline in NYHA/Ross functional class</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>NYHA/Ross functional class will be compared through 52 weeks of double-blind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from baseline in Patient Global impression of severity score (PGIS) scale</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>PGIS scale will be compared for LCZ696 and enalapril through 52 weeks of double-blind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Clearance from plasma in steady state (CL,ss)</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter clearance will be estimated to be used in model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Volume of distribution in steady state</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter volume of distribution will be estimated to be used in model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Absorption rate constant in steady state (Ka,ss)</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter Ka will be estimated to be used in model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Time required to drug concentration to decrease by half in steady state (T 1/2,ss)</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter T 1/2 will be estimated to be used in model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Maximum drug concentration in plasma at steady state (Cmax,ss)</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter Cmax will be estimated to be used in model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): Lowest plasma concentration observed during a dosing interval at steady state (Cmin,ss)</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter Cmin will be estimated to be used in model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Population PK of LCZ696 analytes (sacubitril, LBQ657, and valsartan): area under the plasma concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss)</measure>
    <time_frame>Week 2, 12, 52</time_frame>
    <description>The steady state population PK parameter AUC will be estimated to be used in model.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Pediatric Heart Failure</condition>
  <arm_group>
    <arm_group_label>Part 1: LCZ696 open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 open label either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril or standard of care for heart failure treatment, if patient consents to participate in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2:LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), 50 mg, 100 mg, 200 mg dosage strengths</description>
    <arm_group_label>Part 1: LCZ696 open label</arm_group_label>
    <arm_group_label>Part 2:LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril will be open label in Part 1 and double blind in Part 2</description>
    <arm_group_label>Part 1: LCZ696 open label</arm_group_label>
    <arm_group_label>Part 2: Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of LCZ696</intervention_name>
    <arm_group_label>Part 2: Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Enalapril</intervention_name>
    <arm_group_label>Part 2:LCZ696</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic heart failure resulting from left ventricular systolic dysfunction, and
             receiving chronic HF therapy (if not newly diagnosed)

          -  NYHA classification II-IV (older children: 6 to &lt;18 years old) or Ross CHF
             classification II-IV (younger children: &lt; 6 years old)

          -  Systemic left ventricular ejection fraction ≤ 40% or fractional shortening ≤20%

          -  For Part 1 study: Patients must be treated with an ACEI or ARB prior to screening.
             Patients in Group 1 and 2 must be currently treated with the dose equivalent of at
             least enalapril 0.2 mg/kg prior to the LCZ696 3.1 mg/kg administration. Group 3
             patients will participate in LCZ696 0.8 mg/kg and not LCZ696 3.1 mg/kg.

          -  Biventricular physiology with systemic left ventricle

        Key Exclusion Criteria:

          -  Patient with single ventricle or systemic right ventricle

          -  Patients listed for heart transplantation (as United Network for Organ Sharing status
             1A) or hospitalized waiting for transplant (while on inotropes or with ventricular
             assist device)

          -  Sustained or symptomatic dysrhythmias uncontrolled with drug or device therapy

          -  Patients that have had cardiovascular surgery or percutaneous intervention to palliate
             or correct congenital cardiovascular malformations within 3 months of the screening
             visit. Patients anticipated to undergo corrective heart surgery during the 12 months
             after entry into Part 2

          -  Patients with unoperated obstructive or severe regurgitant valvular (aortic,
             pulmonary, or tricuspid) disease, or significant systemic ventricular outflow
             obstruction or aortic arch obstruction

          -  Patients with restrictive or hypertrophic cardiomyopathy

          -  Active myocarditis

          -  Renal vascular hypertension (including renal artery stenosis)

          -  Moderate-to severe obstructive pulmonary disease

          -  Serum potassium &gt; 5.3 mmol/L

          -  History of angioedema

          -  Allergy or hypersensitivity to ACEI / ARB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5238</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongsangnam-Do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santurce</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70421</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric Heart failure,</keyword>
  <keyword>systemic left ventricle,</keyword>
  <keyword>reduced ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

